Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2009 (2009), Article ID 472831, 6 pages
http://dx.doi.org/10.1155/2009/472831
Review Article

Review of Topical Treatment of Upper Tract Urothelial Carcinoma

Department of Urology, University of Iowa, 200 Hawkins Dr., 3 RCP, Iowa City, IA 52242-1089, USA

Received 30 April 2008; Accepted 15 September 2008

Academic Editor: Norm D. Smith

Copyright © 2009 Kenneth G. Nepple et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. X. Keeley, Jr. and D. H. Bagley, “Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma,” The Journal of Urology, vol. 158, no. 6, pp. 2074–2077, 1997. View at Publisher · View at Google Scholar
  2. F. N. Joudi, C. N. Crane, and M. A. O'Donnell, “Minimally invasive management of upper tract urothelial carcinoma,” Current Urology Reports, vol. 7, no. 1, pp. 23–30, 2006. View at Publisher · View at Google Scholar
  3. D. S. Elliott, J. W. Segura, D. Lightner, D. E. Patterson, and M. L. Blute, “Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney,” Urology, vol. 58, no. 2, pp. 174–178, 2001. View at Publisher · View at Google Scholar
  4. M. C. Hall, S. S. Chang, G. Dalbagni et al., “Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update,” The Journal of Urology, vol. 178, no. 6, pp. 2314–2330, 2007. View at Publisher · View at Google Scholar · View at PubMed
  5. F. N. Joudi, B. J. Smith, and M. A. O'Donnell, “Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer,” Urologic Oncology, vol. 24, no. 4, pp. 344–348, 2006. View at Publisher · View at Google Scholar · View at PubMed
  6. D. L. Lamm, B. A. Blumenstein, J. D. Crissman et al., “Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study,” The Journal of Urology, vol. 163, no. 4, pp. 1124–1129, 2000. View at Publisher · View at Google Scholar
  7. H. Yokogi, Y. Wada, M. Mizutani, M. Igawa, and T. Ishibe, “Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract,” British Journal of Urology, vol. 77, no. 5, pp. 676–679, 1996. View at Publisher · View at Google Scholar
  8. Y. Nishino, N. Yamamoto, H. Komeda, Y. Takahashi, and T. Deguchi, “Bacillus Calmette-Guérin instillation treatment for carcinoma in situ of the upper urinary tract,” BJU International, vol. 85, no. 7, pp. 799–801, 2000. View at Publisher · View at Google Scholar
  9. N. Nonomura, Y. Ono, M. Nozawa et al., “Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract,” European Urology, vol. 38, no. 6, pp. 701–705, 2000. View at Publisher · View at Google Scholar
  10. O. Yossepowitch, D. A. Lifshitz, Y. Dekel et al., “Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation,” The Journal of Urology, vol. 173, no. 3, pp. 890–893, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. H. Miyake, H. Eto, S. Hara, H. Okada, S. Kamidono, and I. Hara, “Clinical outcome of bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract,” International Journal of Urology, vol. 9, no. 12, pp. 677–680, 2003. View at Publisher · View at Google Scholar
  12. A. Patel and G. J. Fuchs, “New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma,” The Journal of Urology, vol. 159, no. 1, pp. 71–75, 1998. View at Publisher · View at Google Scholar
  13. G. N. Thalmann, R. Markwalder, B. Walter, and U. E. Studer, “Long-term experience with bacillus Calmette-Guérin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery,” The Journal of Urology, vol. 168, no. 4, part 1, pp. 1381–1385, 2002. View at Publisher · View at Google Scholar
  14. J. A. Burns, R. D. Williams, S. P. Hedican, and M. A. O'Donnell, “The treatment of upper tract transitional cell carcinoma with BCG plus interferon-alpha,” in Proceedings of the North Central Section of the American Urological Association Annual Meeting, Cancun, Mexico, October 2001.
  15. X. Chen, Y. Luo, H. Yamada, and M. A. O'Donnell, “BCG potentiates human chemokine induction in vivo and in vitro,” The Journal of Urology, vol. 165, p. 114, abstract no. 465, 2001. View at Google Scholar
  16. M. H. Katz, M. W. Lee, and M. Gupta, “Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-α2B,” Journal of Endourology, vol. 21, no. 4, pp. 374–377, 2007. View at Publisher · View at Google Scholar · View at PubMed
  17. J. A. Martínez-Piñeiro, Ma. J. García Matres, and L. Martínez-Piñeiro, “Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors,” The Journal of Urology, vol. 156, no. 2, pp. 377–385, 1996. View at Publisher · View at Google Scholar
  18. D. S. Elliott, M. L. Blute, D. E. Patterson, E. J. Bergstralh, and J. W. Segura, “Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma,” Urology, vol. 47, no. 6, pp. 819–825, 1996. View at Publisher · View at Google Scholar
  19. T. W. Jarrett, P. M. Sweetser, G. H. Weiss, and A. D. Smith, “Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience,” The Journal of Urology, vol. 154, no. 5, pp. 1629–1635, 1995. View at Publisher · View at Google Scholar
  20. J. Palou, L. F. Piovesan, J. Huguet, J. Salvador, J. Vicente, and H. Villavicencio, “Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup,” The Journal of Urology, vol. 172, no. 1, pp. 66–69, 2004. View at Publisher · View at Google Scholar · View at PubMed
  21. J. L. Maymi, N. Saltsgaver, and M. A. O'Donnell, “Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer,” The Journal of Urology, vol. 175, p. 271, abstract no. 840, 2006. View at Google Scholar